Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;9(6):448-54.
doi: 10.1631/jzus.B0820050.

Losartan reduced connexin43 expression in left ventricular myocardium of spontaneously hypertensive rats

Li-li Zhao  1 , Hong-juan Chen, Jun-zhu Chen, Min Yu, Yun-lan Ni, Wei-fang Zhang
Affiliations

Losartan reduced connexin43 expression in left ventricular myocardium of spontaneously hypertensive rats

Li-li Zhao et al. J Zhejiang Univ Sci B. 2008 Jun.

Abstract

Objective: To assess the effect of angiotensin II type 1 (AT(1)) receptor antagonist losartan on myocardium connexin43 (Cx43) gap junction (GJ) expression in spontaneously hypertensive rats (SHRs) and investigate possible mechanisms.

Methods: Sixteen 9-week-old male SHRs and 8 age-matched male Wistar-Kyoto (WKY) rats were included in this study. SHRs were randomly divided into two groups to receive losartan at 30 mg/(kg x d) by oral gavage once daily for 8 weeks (SHR-L) or vehicle (0.9% saline) to act as controls (SHR-V); WKY rats receiving vehicle for 8 weeks served as normotensive controls. At the end of the experiment, rats were sacrificed and the hearts were removed. Expressions of Cx43 and nuclear factor-kappaB p65 (NF-kappaB p65) proteins in all three groups were observed and further investigations on the effect of angiotensin II type 1 receptor antagonist losartan (30 mg/(kg x d), 8 weeks) on Cx43 expression were conducted with Western blot and immunohistochemistry. NF-kappaB p65 protein in nuclear extracts was determined by Western blot.

Results: Left ventricular (LV) hypertrophy was prominent in SHRs, Cx43 and NF-kappaB p65 protein expressions were obviously upregulated and Cx43 distribution was dispersed over the cell surface. Treatment with losarton reduced the over-expressions of Cx43 and NF-kappaB p65 in LV myocardium. The distribution of Cx43 gap junction also became much regular and confined to intercalated disk after losartan treatment.

Conclusion: Cx43 level was upregulated in LV myocardium of SHR during early stage of hypertrophy. Angiotensin II type 1 receptor antagonist losartan prevented Cx43 gap junction remodeling in hypertrophied left ventricles, possibly through the NF-kappaB pathway.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pathological changes of left ventricular cardiocytes in three groups (HE stain). (a) In WKY-V group, cardiocytes with normal size were regular; (b) In SHR-V group, the increased sizes of cardiocytes and myofiber disarray were prominent; (c) In SHR-L group, ventricular cardiocytes with decreased size after treatment with 30 mg/(kg·d) losartan were more regular than those in untreated group
Fig. 1
Fig. 1
Pathological changes of left ventricular cardiocytes in three groups (HE stain). (a) In WKY-V group, cardiocytes with normal size were regular; (b) In SHR-V group, the increased sizes of cardiocytes and myofiber disarray were prominent; (c) In SHR-L group, ventricular cardiocytes with decreased size after treatment with 30 mg/(kg·d) losartan were more regular than those in untreated group
Fig. 1
Fig. 1
Pathological changes of left ventricular cardiocytes in three groups (HE stain). (a) In WKY-V group, cardiocytes with normal size were regular; (b) In SHR-V group, the increased sizes of cardiocytes and myofiber disarray were prominent; (c) In SHR-L group, ventricular cardiocytes with decreased size after treatment with 30 mg/(kg·d) losartan were more regular than those in untreated group
Fig. 2
Fig. 2
Changes of spatial organization of Cx43 in LV myocardium determined by immunohistochemistry. (a) In WKY-V group, the distribution of Cx43 was homogeneous in normal ventricular myocardium; (b) In SHR-V group, the distribution of Cx43 was heterogeneous; (c) In SHR-L group, the distribution of Cx43 was much regular after treatment with 30 mg/(kg·d) losartan
Fig. 2
Fig. 2
Changes of spatial organization of Cx43 in LV myocardium determined by immunohistochemistry. (a) In WKY-V group, the distribution of Cx43 was homogeneous in normal ventricular myocardium; (b) In SHR-V group, the distribution of Cx43 was heterogeneous; (c) In SHR-L group, the distribution of Cx43 was much regular after treatment with 30 mg/(kg·d) losartan
Fig. 2
Fig. 2
Changes of spatial organization of Cx43 in LV myocardium determined by immunohistochemistry. (a) In WKY-V group, the distribution of Cx43 was homogeneous in normal ventricular myocardium; (b) In SHR-V group, the distribution of Cx43 was heterogeneous; (c) In SHR-L group, the distribution of Cx43 was much regular after treatment with 30 mg/(kg·d) losartan
Fig. 3
Fig. 3
Western blot analysis of Cx43 and NF-κB p65 in three groups. (a) Representative Cx43 immunoblot (upper panel) and relative Cx43 protein levels (lower panel, mean±SD); (b) Representative NF-κB p65 immunoblot (upper panel) and relative NF-κB p65 protein levels (lower panel, mean±SD) * P<0.05 vs WKY-V group, # P<0.05 vs SHR-V group; ** P<0.001 vs WKY-V group; ## P<0.001 vs SHR-V group
Fig. 3
Fig. 3
Western blot analysis of Cx43 and NF-κB p65 in three groups. (a) Representative Cx43 immunoblot (upper panel) and relative Cx43 protein levels (lower panel, mean±SD); (b) Representative NF-κB p65 immunoblot (upper panel) and relative NF-κB p65 protein levels (lower panel, mean±SD) * P<0.05 vs WKY-V group, # P<0.05 vs SHR-V group; ** P<0.001 vs WKY-V group; ## P<0.001 vs SHR-V group
See this image and copyright information in PMC

References

    1. Cai W, Ruan LM, Wang YN, Chen JZ. Effects of angiotensin II on connexin43 of VSMCs in arteriosclerosis. J Zhejiang Univ Sci B. 2006;7(8):648–653. doi: 10.1631/jzus.2006.B0648. - DOI - PMC - PubMed
    1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995–1003. doi: 10.1016/S0140-6736(02)08089-3. - DOI - PubMed
    1. Dodge SM, Beardslee MA, Darrow BJ, Green KG, Beyer EC, Saffitz JE. Effects of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes. J Am Coll Cardiol. 1998;32(3):800–807. doi: 10.1016/S0735-1097(98)00317-9. - DOI - PubMed
    1. Emdad L, Uzzaman M, Takagshi Y, Honjo H, Uchida T, Severs NJ, Kodama I, Murata Y. Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: prevention by angiotensin II type 1 receptor blockade. J Mol Cell Cardiol. 2001;33(2):219–231. doi: 10.1006/jmcc.2000.1293. - DOI - PubMed
    1. Gupta S, Purcell NH, Lin A, Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol. 2002;159(6):1019–1028. doi: 10.1083/jcb.200207149. - DOI - PMC - PubMed

MeSH terms